National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 742949

Case Details

VAERS ID: 742949 (history)  
Form: Version 2.0  
Age: 11.0  
Sex: Female  
Location: Unknown  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 0000-00-00
Entered: 2018-04-03
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 1 UN / UN

Administered by: Unknown       Purchased by: ?
Symptoms: Abdominal pain, Abdominal pain upper, Alopecia, Amnesia, Anti-NMDA antibody negative, Anti-thyroid antibody negative, Antibody test negative, Antiphospholipid antibodies negative, Anxiety, Arthralgia, Autoantibody positive, Autonomic neuropathy, Bedridden, Biopsy skin abnormal, Cardiac monitoring normal, Cardiovascular disorder, Chest pain, Cognitive disorder, Deafness, Disability, Dyspnoea, Echocardiogram normal, Fatigue, Gait disturbance, Headache, Immunoglobulin therapy, Insomnia, Laboratory test normal, Migraine, Mouth ulceration, Muscle twitching, Muscular weakness, Nasal crusting, Nuclear magnetic resonance imaging brain normal, Pallor, Paraesthesia, Postural orthostatic tachycardia syndrome, Pyrexia, Raynaud's phenomenon, Reflex test abnormal, Small fibre neuropathy, Syncope, Tilt table test positive, Tinnitus, Vertigo, Viral infection, Vomiting
SMQs:, Torsade de pointes/QT prolongation (broad), Rhabdomyolysis/myopathy (broad), Severe cutaneous adverse reactions (broad), Anaphylactic reaction (broad), Acute pancreatitis (broad), Peripheral neuropathy (narrow), Neuroleptic malignant syndrome (broad), Systemic lupus erythematosus (broad), Anticholinergic syndrome (broad), Arrhythmia related investigations, signs and symptoms (broad), Retroperitoneal fibrosis (broad), Dementia (broad), Malignancy related therapeutic and diagnostic procedures (narrow), Dyskinesia (broad), Dystonia (broad), Parkinson-like events (broad), Oropharyngeal conditions (excl neoplasms, infections and allergies) (narrow), Acute central respiratory depression (broad), Pulmonary hypertension (broad), Guillain-Barre syndrome (broad), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Cardiomyopathy (broad), Hearing impairment (narrow), Vestibular disorders (narrow), Skin tumours of unspecified malignancy (broad), Hypotonic-hyporesponsive episode (broad), Hypersensitivity (broad), Arthritis (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Hypoglycaemia (broad), Dehydration (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? Yes
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Familial risk factor
Preexisting Conditions: Medical History/Concurrent Conditions: Infection; Sinus operation
Allergies:
Diagnostic Lab Data:
CDC Split Type: US0095075131803USA011781

Write-up: This literature marketed report has been received from the authors of a published article and refers to an 11-year-old patient. On an unknown date, the patient received her first dose of GARDASIL vaccine (dose, route of administration, lot# and expiration date were not reported) at a well-child visit. She had been healthy aside from sinus surgery and frequent infections. Prior immunology evaluation was negative, but there was a family history of autoimmune disease. Two days postvaccination, she developed headache and vomiting thought due to a viral illness. Her symptoms were progressive, however, and by 5 to 6 weeks postvaccination, there was abdominal pain, frequent vomiting, severe fatigue, pallor, daily syncope, chest pain, dyspnea, low-grade fevers, arthralgias, daily headache, memory loss, tinnitus, hearing loss, vertigo, unsteady gait, leg weakness, muscle twitches, paresthesias, and insomnia. By 7 weeks postvaccination, she had become bed-bound. She also developed moderate alopecia, Raynaud''s phenomenon, recurrent oral ulcers, and nasal scabbing, suggesting the possibility of systemic autoimmunity. Eight months postvaccination, she was diagnosed with postural tachycardia syndrome (POTS) and neurocardiogenic syncope (NCS) by tilt table testing and autonomic reflex testing revealed abnormal blood pressure response to Valsalva and reduced baroreflex adrenergic sensitivity. Nonautoimmune causes for her symptoms were excluded with laboratory testing, echocardiogram, cardiac monitoring and brain magnetic resonance imaging. The autoimmune dysautonomia panel antibodies, NMDA (N-methyl-d-aspartate) receptor antibodies, thyroid antibodies, and celiac antibodies were all negative. Testing for Sjogren''s syndrome (including the early Sjogren''s antibodies), antiphospholipid syndrome (with primary and secondary antibodies) and lupus was also negative. However, autoantibodies against adrenergic and muscarinic receptors were detected (Anti-beta-1 adrenergic receptor antibodies: 21.7 units/ml (positive), anti-?beta-2 adrenergic receptor antibodies: 11.4 units/ml (indeterminate), anti-muscarinic cholinergic receptor-3 antibodies:13.5 units/ml (positive) and anti-muscarinic cholinergic receptor-4 antibodies: 24.9 units/ml (positive)). The patient did improve with conservative therapy, but she remained moderate to severely disabled by her illness. Small fiber neuropathy was suspected due to her cardiovascular and presumed gastrointestinal autonomic dysfunction as well as the presence of muscle twitches and paresthesias, and a skin biopsy was performed (from the lower legs as normative data were available) to evaluate for this possibility (biopsy results: Epidermal Nerve Fiber Density: left lower leg: 8.1/mm (normal), right lower leg: 8.6/mm (normal); Sweat Gland Nerve Fiber Density: left lower leg:16.7% (abnormal), right lower leg: 27.5% (abnormal). Given the patient''s young age (13 years at the time of the biopsy), these results were consistent with a very severe autonomic neuropathy and likely a mild to moderate small fiber sensory neuropathy. Given evidence for autoimmune autonomic neuropathy, a trial of intravenous immunoglobulin therapy was initiated. After four months of therapy at a dose of 1 gm/kg monthly, the patient continues to gradually improve. Her COMPASS-31 score has improved from 46 to 29 and her estimated level of functioning has improved from 20% (mostly bedridden) to 60% (more good days than bad days). The earliest signs of improvement came after the second week of treatment. Her recurrent syncope and paresthesias have resolved. Her epigastric pain, migraines, insomnia, anxiety, fatigue, and cognitive ability have all moderately improved and she had been able to stop her biweekly saline infusions. She continued on monthly intravenous immunoglobulin. The outcome of autonomic neuropathy, syncope, small fibre neuropathy and autoimmune neuropathy was reported as recovered/resolved. The outcome of systemic immune activation and postural orthostatic tachycardia syndrome was reported as recovering/resolving. The authors considered postural orthostatic tachycardia syndrome, systemic immune activation, autoimmune neuropathy, small fibre neuropathy, autonomic neuropathy and syncope to be related to GARDASIL. All the events were considered to be disabling by the reporter. Upon internal review, the events of systemic immune activation, autoimmune neuropathy and autonomic neuropathy were considered to be medically significant.


New Search

Link To This Search Result:

https://www.medalerts.org/vaersdb/findfield.php?IDNUMBER=742949


Copyright © 2020 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166